424 research outputs found
Eine Frage der Galenik? Neue Formulierung von Imiquimod in der Therapie aktinischer Keratosen
No full textIV, 71 Seiten ; Diagramm
Emeline Renz, CSCJ Supplemental Assignments, Spring 2020
No full textCSCJ Supplemental Assignments, Spring 2020. Submitted by Emeline Renz, GIS Coordinator, Sociology and Criminal Justice Department, Clark Atlanta University
NMDA receptors in health and diseases: new roles and signaling pathways - Anti-N-Methyl-D-Aspartate Receptor (NMDAR) autoantibodies as potential biomarkers of fatigue in patients with rheumatic diseases
No full textFatigue is a widespread and complex symptom with motor and cognitive components;
it is diagnosed predominantly by questionnaire. We recently published a correlation between anti-
N-methyl-D-aspartate receptor (NMDAR) antibodies and fatigue in patients with SLE (systemic
lupus erythematosus). In the present study, we examined whether this association also applies
to patients with other rheumatic diseases. Serum samples of 88 patients with different rheumatic
diseases were analyzed for the presence of anti-NR2 antibodies and Neurofilament light chain (NfL)
protein. The severity of fatigue was determined according to the FSMC questionnaire (Fatigue Scale
for Motor and Cognitive Functions) and correlated with the circulating antibody titer and NfL level
accordingly. Positive titers of anti-NR2 antibodies were detected in patients with both autoimmune
and non-autoimmune rheumatic diseases. These patients suffer predominantly from severe fatigue.
The circulating NfL level did not correlate with the anti-NR2 titer and the fatigue severity in all
patient groups. The association of severe fatigue with circulating anti-NR2 antibodies in patients
with rheumatic diseases, independently from the main disease, suggests an individual role of these
autoantibodies in fatigue pathophysiology. Thus, the detection of these autoantibodies might be a
helpful diagnostic tool in rheumatic patients with fatigue.30 Seiten ; Diagramm
Emeline Renz, Clark Atlanta University, April 20, 2020
No full textStatement submitted by Emeline Renz, GIS Coordinator (Faculty/Staff), Sociology and Criminal Justice Department, Clark Atlanta University
Drug Survival in the Treatment of Mucosal Lichen Planus: A Retrospective Multicenter Study
No full textBackground and Objectives: Mucosal lichen planus (LP) is a rare chronic inflammatory skin disease. Its treatment is difficult and comparative data on the sustainability of different drugs are lacking. We aimed to retrospectively assess patient and disease characteristics and analyze drug survival rates in the treatment of mucosal LP under real‐world conditions. Patients and Methods: Our retrospective study included patients with mucosal LP treated systemically in the dermatology departments of five German University Medical Centers between 01/2005 and 03/2022. Patient and disease characteristics and treatment responses were evaluated. Drug survival from systemic therapies was assessed by Kaplan–Meier analysis and multivariate regression. Results: Overall, 281 patients with a total of 407 treatment courses were identified. The overall median drug survival was 5.0 months (conventional drugs: 5.0 months vs. novel drugs [biologicals and Janus kinase inhibitors]: 17.0 months, p = 0.029). Among conventional drugs, median drug survival was numerically the highest for methotrexate (13.0 months), followed by mycophenolate mofetil (12.0 months); hydroxychloroquine (9.0 months); acitretin and cyclosporine (6.0 months each); azathioprine, dapsone, and other retinoids (5.0 months each); and finally glucocorticoids (2.0 months). Among novel drugs, median drug survival was numerically the highest in TNF‐α blockers and IL‐17 antagonists (median: 21.0 and 17.0 months, respectively), while median drug survival for Janus kinase inhibitors has not yet been reached. Altogether, the outcomes were documented in 68.6% of cases, with excellent (33.5%), partial (34.5%) or nonresponse (32.0%) in one‐third of cases each. The group of novel therapies comprising biologicals and Janus kinase inhibitors was significantly more effective than the group of conventional drugs (excellent response: 66.7%, 8/12 vs. 32.1%, 83/258; P = 0.013, χ 2 ‐test). Conclusions: In addition to glucocorticoids, cyclosporine, mycophenolate mofetil, and methotrexate (plus hydroxychloroquine), biologicals and Janus kinase inhibitors in particular seem to be therapeutic options for the treatment of mucosal LP, which is worth investigating further.Open-Access-Publikationsfonds 202
Hereditary angioedema (HAE) in children and adolescents : a consensus on therapeutic strategies
No full textHereditary angioedema due to C1 inhibitor (C1 esterase inhibitor) deficiency (types I and II HAE-C1-INH) is a rare disease that usually presents during childhood or adolescence with intermittent episodes of potentially life-threatening angioedema. Diagnosis as early as possible is important to avoid ineffective therapies and to properly treat swelling attacks. At a consensus meeting in June 2011, pediatricians and dermatologists from Germany, Austria, and Switzerland reviewed the currently available literature, including published international consensus recommendations for HAE therapy across all age groups. Published recommendations cannot be unconditionally adopted for pediatric patients in German-speaking countries given the current approval status of HAE drugs. This article provides an overview and discusses drugs available for HAE therapy, their approval status, and study results obtained in adult and pediatric patients. Recommendations for developing appropriate treatment strategies in the management of HAE in pediatric patients in German-speaking countries are provided.Conclusion Currently, plasma-derived C1 inhibitor concentrate is considered the best available option for the treatment of acute HAE-C1-INH attacks in pediatric patients in German-speaking countries, as well as for short-term and long-term prophylaxis
- …
